158 related articles for article (PubMed ID: 21324346)
1. Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients.
Gambichler T; Kobus S; Kobus A; Tigges C; Scola N; Altmeyer P; Kreuter A; Bechara FG; Skrygan M
Regul Pept; 2011 Apr; 167(2-3):163-6. PubMed ID: 21324346
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of antimicrobial peptides in psoriasis and psoriatic arthritis as a novel contributory mechanism for skin and joint disease heterogeneity.
Bierkarre H; Harder J; Cuthbert R; Emery P; Leuschner I; Mrowietz U; Hedderich J; McGonagle D; Gläser R
Scand J Rheumatol; 2016; 45(3):188-96. PubMed ID: 26599663
[TBL] [Abstract][Full Text] [Related]
3. Visfatin enhances the production of cathelicidin antimicrobial peptide, human β-defensin-2, human β-defensin-3, and S100A7 in human keratinocytes and their orthologs in murine imiquimod-induced psoriatic skin.
Hau CS; Kanda N; Noda S; Tatsuta A; Kamata M; Shibata S; Asano Y; Sato S; Watanabe S; Tada Y
Am J Pathol; 2013 May; 182(5):1705-17. PubMed ID: 23499548
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury.
Harder J; Dressel S; Wittersheim M; Cordes J; Meyer-Hoffert U; Mrowietz U; Fölster-Holst R; Proksch E; Schröder JM; Schwarz T; Gläser R
J Invest Dermatol; 2010 May; 130(5):1355-64. PubMed ID: 20107483
[TBL] [Abstract][Full Text] [Related]
5. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus.
Kreuter A; Jaouhar M; Skrygan M; Tigges C; Stücker M; Altmeyer P; Gläser R; Gambichler T
J Am Acad Dermatol; 2011 Jul; 65(1):125-33. PubMed ID: 21353331
[TBL] [Abstract][Full Text] [Related]
6. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
[TBL] [Abstract][Full Text] [Related]
7. Significant upregulation of antimicrobial peptides and proteins in lichen sclerosus.
Gambichler T; Skrygan M; Tigges C; Kobus S; Gläser R; Kreuter A
Br J Dermatol; 2009 Nov; 161(5):1136-42. PubMed ID: 19558556
[TBL] [Abstract][Full Text] [Related]
8. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa.
Emelianov VU; Bechara FG; Gläser R; Langan EA; Taungjaruwinai WM; Schröder JM; Meyer KC; Paus R
Br J Dermatol; 2012 May; 166(5):1023-34. PubMed ID: 22136668
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
Lizzul PF; Aphale A; Malaviya R; Sun Y; Masud S; Dombrovskiy V; Gottlieb AB
J Invest Dermatol; 2005 Jun; 124(6):1275-83. PubMed ID: 15955104
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of antimicrobial peptides and proteins do not correlate with psoriasis severity and are increased after treatment with fumaric acid esters.
Gambichler T; Bechara FG; Scola N; Rotterdam S; Altmeyer P; Skrygan M
Arch Dermatol Res; 2012 Aug; 304(6):471-4. PubMed ID: 22410863
[TBL] [Abstract][Full Text] [Related]
11. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Stramazzotti D; Morichetti D; Bernardini ML; Mannello B; Fabris G; Offidani A
Br J Dermatol; 2007 Dec; 157(6):1155-60. PubMed ID: 17916208
[TBL] [Abstract][Full Text] [Related]
12. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
13. [Refractory psoriasis treatment with etanercept].
Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Pérez-Ferriols A; Soriano Navarro CJ; Fortea Baixauli JM
Med Clin (Barc); 2005 Sep; 125(10):371-3. PubMed ID: 16185546
[TBL] [Abstract][Full Text] [Related]
14. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.
Antiga E; Volpi W; Cardilicchia E; Maggi L; Filì L; Manuelli C; Parronchi P; Fabbri P; Caproni M
J Clin Immunol; 2012 Dec; 32(6):1221-32. PubMed ID: 22699761
[TBL] [Abstract][Full Text] [Related]
15. Endogenous antimicrobial peptides and skin infections in atopic dermatitis.
Ong PY; Ohtake T; Brandt C; Strickland I; Boguniewicz M; Ganz T; Gallo RL; Leung DY
N Engl J Med; 2002 Oct; 347(15):1151-60. PubMed ID: 12374875
[TBL] [Abstract][Full Text] [Related]
16. Differential expression pattern of antimicrobial peptides in nasal mucosa and secretion.
Laudien M; Dressel S; Harder J; Gläser R
Rhinology; 2011 Mar; 49(1):107-11. PubMed ID: 21468384
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
18. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.
Iyer S; Yamauchi P; Lowe NJ
Br J Dermatol; 2002 Jan; 146(1):118-21. PubMed ID: 11841377
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
20. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
